Trastuzumab in the treatment of advanced non-small-cell lung cancer: is there a role? Focus on Eastern Cooperative Oncology Group study 2598.
about
Recent advances of novel targeted therapy in non-small cell lung cancerRole of HER2 in NSCLCSystemic and targeted therapies for early-stage lung cancerHER2 driven non-small cell lung cancer (NSCLC): potential therapeutic approachesTrastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance.Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic ImplicationsRole of HGF/MET axis in resistance of lung cancer to contemporary management.Targeted therapy in NSCLC driven by HER2 insertionsHER2 in solid tumors: more than 10 years under the microscope; where are we now?Monoclonal antibodies as effective therapeutic agents for solid tumors.Therapeutic targeting of receptor tyrosine kinases in lung cancer.Perspectives on novel therapies for bronchial carcinoma.p95HER2 truncated form in resected non-small cell lung cancerThe frequency and clinical impact of HER2 alterations in lung adenocarcinoma.Tailor-made chemotherapy for non-small cell lung cancer patients.Epidermal growth factor receptor inhibitors and antiangiogenic agents for the treatment of non-small cell lung cancer.Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines.New targetable oncogenes in non-small-cell lung cancer.Activating Mutations in ERBB2 and Their Impact on Diagnostics and Treatment.New targets for non-small-cell lung cancer therapy.Somatic pharmacogenomics in cancer.Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas.Trends in therapeutic monoclonal antibodies of cancer.Reproducibility of the EGFR immunohistochemistry scores for tumor samples from patients with advanced non-small cell lung cancerRare mutations in non-small-cell lung cancer.HER2 and lung cancer.Molecular analysis of cell-free circulating DNA for the diagnosis of somatic mutations associated with resistance to tyrosine kinase inhibitors in non-small-cell lung cancer.Rationale for targeting the ErbB family of receptors in patients with advanced squamous cell carcinoma of the lung.Prognostic and predictive biomarkers for targeted therapy in NSCLC: for whom the bell tolls?Emerging targeted therapies in non-small cell lung cancer.Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.HER2 mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium.In vitro antiproliferative effect of trastuzumab (Herceptin(®)) combined with cetuximab (Erbitux(®)) in a model of human non-small cell lung cancer expressing EGFR and HER2.Orthotopic models of esophageal carcinoma and their use in drug discovery.Understanding and targeting resistance mechanisms in NSCLC.Impact of HER2 codon 655 polymorphism and expression of HER2 and HER3 in non small cell lung cancer patients.Establishment and characterization of esophageal squamous cell carcinoma patient-derived xenograft mouse models for preclinical drug discovery.Activating HER2 mutations as emerging targets in multiple solid cancers.
P2860
Q21092930-89458043-7A76-441D-BC6C-4D3DFDAA1601Q26781683-743C33FD-818E-4BAC-ADEE-5F11DCDA2065Q26865490-EA98CD31-3687-447F-99F7-8389BE5C756CQ26866534-AABBDB8B-9613-46AD-83F7-2B20EC6EA1B9Q27853015-EF8A470A-33A7-4706-9276-A45696DF0EF9Q34223494-D3F072D3-8A85-4A08-BB5B-4549B5210A90Q35200337-5EBD8A68-0B57-475A-A3C4-B53A099DC771Q35200528-771BBFDD-4C23-459A-82D1-9D6C2E2E2C83Q35211263-A5629D49-E3AA-4C07-837D-A95B84F93A53Q35857856-2E54EA28-9210-4E69-8ED3-10E645FCAEADQ36158717-0AB1A89F-D139-403E-997D-44673279E132Q36163982-65E12931-0E6B-4A15-B73C-5B5F505E32DDQ36170889-4CFD8CC5-875C-4C78-AE5D-822CF38A7208Q36266449-DC0AC89F-4336-4630-B09F-5A467BDE1CA9Q36430761-25507407-39B5-42E9-A54C-D1AF6314AD9FQ36482542-F67BF6E7-049B-42E1-93AE-2163592857D3Q36624335-6457774B-D9AD-489D-85BF-EC10C6A60429Q36660677-C4F2A605-B4D0-4D08-8CF7-B37C05870BC6Q36785721-5896451E-9C2D-41E9-A009-249567CE871CQ36974703-8293B7E1-6CBC-4A2E-9A44-622B14B1E4A0Q37235024-F16CCFE4-53F6-4520-B858-F5632885C634Q37398636-1F750272-A69B-4809-A322-EA19B61A40B1Q37689796-745273F0-CEB7-4EDF-BDB1-6B3823486494Q37701159-121551B7-433C-435D-962A-19385D782E8BQ38104414-8AF25060-CA7A-4630-AF6C-DD844AEBACE8Q38153447-80C86716-885B-4B25-9D83-41E219614A3DQ38203956-891C239E-9730-417D-99CD-BAC9804EC11BQ38514601-0F5D62DE-9ACA-458D-B34B-CF6BBF00184FQ38584814-7E6C4856-28E4-4724-9FCF-2B1E521C288BQ38653045-09C441A7-AE20-4D62-B8B6-D27A61FCC1D0Q38653663-F643C5EE-E6AA-46AC-A3D2-8AB447A09EEAQ38661973-07B35766-EB65-46E7-96A7-8761C4585C47Q38905987-30ABD050-78A3-4746-8A90-15FC4B26A90FQ39478437-5257164B-634B-4C78-9BCA-CCA615BD3232Q46915997-D8820BC6-707F-4E0A-97C0-3BD60AC53026Q50877452-3D053316-894D-4D48-9C0B-F6DB2216A6A4Q51512708-74BBF878-1C8A-4D81-9CA2-D045839AF4E2Q54986604-2224D45D-F466-4382-A211-0131088BABA1
P2860
Trastuzumab in the treatment of advanced non-small-cell lung cancer: is there a role? Focus on Eastern Cooperative Oncology Group study 2598.
description
2004 nî lūn-bûn
@nan
2004 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Trastuzumab in the treatment o ...... ive Oncology Group study 2598.
@ast
Trastuzumab in the treatment o ...... ive Oncology Group study 2598.
@en
type
label
Trastuzumab in the treatment o ...... ive Oncology Group study 2598.
@ast
Trastuzumab in the treatment o ...... ive Oncology Group study 2598.
@en
prefLabel
Trastuzumab in the treatment o ...... ive Oncology Group study 2598.
@ast
Trastuzumab in the treatment o ...... ive Oncology Group study 2598.
@en
P2093
P356
P1476
Trastuzumab in the treatment o ...... ive Oncology Group study 2598.
@en
P2093
Corey J Langer
David H Johnson
Eastern Cooperative Oncology Group Study 2598
Mark Vangel
Patricia Stephenson
P304
P356
10.1200/JCO.2004.04.105
P407
P577
2004-02-23T00:00:00Z